Clinical Trial

ANCA II - Quality of Life and Functional Outcome in Patients With Anal Cancer

Study acronym: ANCAII
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 8, 2023 (before its estimated April 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
Anal cancer is a rare disease, but the incidence is rising. About 200 patients will get this type of cancer yearly in Sweden. Curative treatment includes chemotherapy and radiotherapy. The prognosis is good, but some patients will have recurrent or persistent disease after concluded chemo-radiotherapy and will then be offered salvage surgery. Some patients develop distant metastases that can be treated with good results. The aim of this study is to identify and describe functional outcome in patients diagnosed with anal cancer. We will study patients from diagnosis, try to identify early toxicity to treatment and then identify long-term morbidity.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2021-03-10; most recent amendment 2023-12-07.
Status change: Not Yet Recruiting → Recruiting 2021-10-16
Trial Details
NCT Number NCT04792892
Lead Sponsor Sahlgrenska University Hospital
Conditions Anal Cancer
Enrollment 600 participants
Start Date 2021-08-01
Primary Completion 2025-04-01 (estimated)
Study Completion 2035-04-01 (estimated)
Updated on ClinicalTrials.gov 2023-12-08